Mar 11, 2020 / 06:05PM GMT
Balaji V. Prasad - Barclays Bank PLC, Research Division - Director
Good afternoon, everyone. Thank you for dialing in. My name is Balaji Prasad. I cover specialty pharma for Barclays. This is a continuation of our virtual healthcare conference. And for the session now, we have with us today the senior management team of Phibro. We have Richard Johnson, CFO; and Donny -- Daniel Bendheim, Senior Vice President -- Executive -- Corporate Strategy. Also, reminder that owing to the nature of this format, there will be no Q&A session at the end of this.
Richard and Donny, thank you for joining us. Would you like to start with an overview and then outlook of how you're seeing the business evolve? And we have a few questions that we can launch into post your overview. Thank you.
Richard G. Johnson - Phibro Animal Health Corporation - CFO
Right. Let me first give a brief overview, and I'll probably just summarize our numbers and our guidance that's out there for the year.
We are a roughly $800 million, a little north of $800 million annual revenue
Phibro Animal Health Corp at Barclays Global Healthcare Conference Transcript
Mar 11, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers